SNMMI meeting offers a special focus on radium-223 dichloride

05/21/2013 | MolecularImaging.net

A number of education sessions at this year's SNMMI Annual Meeting will focus on the newly approved radium-223 dichloride, a targeted radioisotope therapy for castrate-resistant prostate cancer, writes SNMMI Outreach Committee Co-chair Dr. Andrei Iagaru. "This is an exciting time for nuclear medicine as alpha radiation is not routinely used as a treatment. Preliminary results are encouraging and many [patient] and referring physician organizations have expressed interest in the new therapy," Iagaru writes.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA